hsa-miR-3202: Hsa-mir-3202 is a microRNA that has been studied in various contexts [PMC9869167]. It has been found to inhibit the proliferation of vascular smooth muscle cells (VSMCs) by suppressing the expression of SLC7A5 [PMC8528547]. It has also been implicated in the regulation of genes involved in thoracic aortic dissection (TAD) [PMC8528547]. Dysregulation of hsa-mir-3202 has been observed in mild traumatic brain disorders and headache attacks [PMC9438144]. In addition, hsa-mir-3202 has been identified as one of the top differentially expressed miRNAs in chronic thromboembolic pulmonary hypertension (CTEPH) and endometrial receptivity [PMC8075669] [PMC6097487]. It is also involved in the regulation of genes related to histamine N-methyltransferase (HNMT) and osteoporosis [PMC9678002] [PMC7543140]. Furthermore, hsa-mir-3202 has been predicted to target TSEN54 and bind to the ORF1a/b region of the SARS-CoV-2 genome [PMC10120902] [PMC9346380]. The ceRNA hypothesis suggests that hsa-mir-3202 can be competitively bound by lncRNAs ARHGAP22-IT1 and SNHG8, leading to upregulation of SLC7A5 and promotion of VSMC proliferation and TAD development [PMC8528547]. Overall, hsa-mir-3202 plays a role in various biological processes and may have diagnostic and therapeutic potential in different diseases.